Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do not meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success

Manish Parikh, Mimi Chung, Sheetal Sheth, Michelle McMacken, Tasneem Zahra, John K. Saunders, Aku UdeWelcome, Van Dunn, Gbenga Ogedegbe, Ann Marie Schmidt, H. Leon Pachter

Research output: Contribution to journalArticle

Abstract

Objective: To compare bariatric surgery versus intensive medicalweight management (MWM) in patients with type 2 diabetes mellitus (T2DM) who do not meet current National Institutes of Health criteria for bariatric surgery and to assess whether the soluble form of receptor for advanced glycation end products (sRAGE) is a biomarker to identify patients most likely to benefit from surgery. Copyright

Background: There are few studies comparing surgery toMWMfor patients with T2DM and BMI less than 35. Methods: Fiftyseven patients with T2DM and BMI 30 to 35, who otherwise met the criteria for bariatric surgery were randomized toMWMversus surgery (bypass, sleeve or band, based on patient preference). The primary outcomes assessed at 6 months were change in homeostatic model of insulin resistance (HOMAIR) and diabetes remission. Secondary outcomes included changes in HbA1c, weight, and sRAGE.

Results: The surgery group had improved HOMAIR ( 4.6 vs +1.6; P = 0.0004) and higher diabetes remission (65% vs 0%, P 0.0001) than the MWM group at 6 months. Compared to MWM, the surgery group had lower HbA1c (6.2 vs 7.8, P = 0.002), lower fasting glucose (99.5 vs 157; P = 0.0068), and fewer T2DMmedication requirements (20% vs 88%; P0.0001) at 6 months. The surgery group lost more weight (7. vs 1.0 BMI decrease, P 0.0001). Higher baseline sRAGE was associated with better weight loss outcomes (r= 0.641; P = 0.046). There were no mortalities.

Conclusions: Surgery was very effective shortterm in patients with T2DM and BMI 30 to 35. Baseline sRAGE may predict patients most likely to benefit from surgery. These findings need to be confirmed with larger studies. ClinicalTrials.gov ID: NCT01423877.

Original languageEnglish (US)
Pages (from-to)617-624
Number of pages8
JournalAnnals of Surgery
Volume260
Issue number4
DOIs
StatePublished - 2014

Keywords

  • BMI under 35
  • Bariatric surgery
  • Diabetes
  • Obesity
  • SRAGE

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do not meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success'. Together they form a unique fingerprint.

  • Cite this